A $62 million Catalent take-or-pay charge separates a revenue beat from an EPS miss, and management still raised the low end of full-year product revenue guidance to $1.25 billion to $1.3 billion. ELEVIDYS volume shrank under its ambulatory-only label while the PMO exon-skipping franchise carried the quarter. DM1 and FSHD dose data land before year end.
Latest Activity
SRPT Coverage
Buy, Sell, or Hold? Tuesday’s Top Upgrades and Downgrades: Cloudflare, Deckers Outdoors, DraftKings, MongoDB, Nike, Oneok, Philip Morris International, Riot Platforms, Wix.com, and More
Pre-Market Stock Futures: Futures are trading mixed, but it’s time to get your popcorn ready, because the October Consumer Price Index will be released this morning at 8:30 ET. Economists project headline…
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with…
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally…
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each…
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size. That equal-weight structure separates it from cap-weighted peers and creates…
The VIX Crashes Out, For Now, on Hope For Peace and Cheaper Oil
The fear gauge pulled back on Wednesday. The CBOE Volatility Index, better known as the VIX, is trading near 25.6 this morning, a drop of roughly 5% from Tuesday’s close of 26.95,…
Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?
Sarepta Therapeutics (NASDAQ:SRPT | SRPT Price Prediction) stock is up approximately 20% in early trading on Wednesday after the company released its first-ever clinical data from two siRNA programs targeting rare neuromuscular…
Prediction: This Pharma Stock Will Be the Best Performer in 2025
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
NFL Team Owner Boosts a Stake, and Other Notable Insider Buying
An NFL team owner continues to boost a stake in an energy stock. Insiders made notable purchases in tech and health care stocks last week as well.
Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Huge Insider Buys at Energy Giants, Bill Ackman Boosts Real Estate Stake Again
Exxon Mobil and another energy giant saw huge insider buys this week, while Bill Ackman continued to build his stake in Howard Hughes.
Monday’s Top Analyst Upgrades and Downgrades: Accenture, Moderna, Tesla, Under Armour, Wayfair, Welltower and More
Monday's top analyst upgrades and downgrades included Academy Sports and Outdoors, Accenture, Clorox, Fiserv, Moderna, Planet Fitness, Sarepta Therapeutics, Tesla, Under Armour, Ventas, Viatris, Wayfair and Welltower.
Tuesday’s Top Analyst Upgrades and Downgrades: Caterpillar, CVS Health, Marvell Technology, Paramount, RingCentral, SoFi, UnitedHealth, Workday and More
Tuesday's top analyst upgrades and downgrades included Broadcom, Caterpillar, CVS Health, Guardant Health, Marvell Technology, Nutrien, Paramount Global, RingCentral, SoFi Technologies, UnitedHealth Group and Workday.
Thursday’s Top Analyst Upgrades and Downgrades: Albertsons, Alphabet, Apple, Coinbase, General Electric, McDonald’s, Microsoft, Tesla and More
Thursday's top analyst upgrades and downgrades included Albertsons Companies, Alphabet, Apple, Coinbase Global, Danaher, Enphase Energy, GE HealthCare Technologies, General Electric, McDonald's, Microsoft, PulteGroup and Tesla.
Wednesday’s Top Analyst Upgrades and Downgrades: American Express, Analog Devices, Boeing, Chevron, Comcast, CSX, Etsy, Prudential Financial and More
Wednesday's top analyst upgrades and downgrades included American Express, Analog Devices, Boeing, Chevron, Chipotle Mexican Grill, Comcast, CSX, Etsy, Fastenal, ONEOK, Prudential Financial, RH and ServiceNow.